Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

Giovanni Paganelli, Carlo Belloni, Patrizia Magnani, Felicia Zito, Andrea Pasini, Isabella Sassi, Mario Meroni, Massimo Mariani, Mario Vignali, Antonio G. Siccardi, Ferruccio Fazio

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 μg of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14% i.d. (range 8-18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56-70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.

Original languageEnglish
Pages (from-to)322-329
Number of pages8
JournalEuropean Journal Of Nuclear Medicine
Volume19
Issue number5
DOIs
Publication statusPublished - May 1992

Fingerprint

Streptavidin
Ovarian Neoplasms
Monoclonal Antibodies
Neoplasms
Radioactivity
Radioimmunotherapy
Indium
Peritoneal Cavity
Ambulatory Surgical Procedures
Photons
Tomography
Urine
Carcinoma
Recurrence
Injections
Antibodies

Keywords

  • Intraperitoneal injection
  • Monoclonal antibody
  • Radioactive streptavidin
  • Tumour pretargetting
  • Two-step

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. / Paganelli, Giovanni; Belloni, Carlo; Magnani, Patrizia; Zito, Felicia; Pasini, Andrea; Sassi, Isabella; Meroni, Mario; Mariani, Massimo; Vignali, Mario; Siccardi, Antonio G.; Fazio, Ferruccio.

In: European Journal Of Nuclear Medicine, Vol. 19, No. 5, 05.1992, p. 322-329.

Research output: Contribution to journalArticle

Paganelli, G, Belloni, C, Magnani, P, Zito, F, Pasini, A, Sassi, I, Meroni, M, Mariani, M, Vignali, M, Siccardi, AG & Fazio, F 1992, 'Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin', European Journal Of Nuclear Medicine, vol. 19, no. 5, pp. 322-329. https://doi.org/10.1007/BF00177053
Paganelli, Giovanni ; Belloni, Carlo ; Magnani, Patrizia ; Zito, Felicia ; Pasini, Andrea ; Sassi, Isabella ; Meroni, Mario ; Mariani, Massimo ; Vignali, Mario ; Siccardi, Antonio G. ; Fazio, Ferruccio. / Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. In: European Journal Of Nuclear Medicine. 1992 ; Vol. 19, No. 5. pp. 322-329.
@article{ed52421ebaf240be955fdc820e9fad06,
title = "Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin",
abstract = "A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 μg of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14{\%} i.d. (range 8-18{\%} i.d.) was found in the urine, 14{\%} i.d. (range 629{\%} i.d.) in the blood and 63{\%} i.d. (range 56-70{\%} i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.",
keywords = "Intraperitoneal injection, Monoclonal antibody, Radioactive streptavidin, Tumour pretargetting, Two-step",
author = "Giovanni Paganelli and Carlo Belloni and Patrizia Magnani and Felicia Zito and Andrea Pasini and Isabella Sassi and Mario Meroni and Massimo Mariani and Mario Vignali and Siccardi, {Antonio G.} and Ferruccio Fazio",
year = "1992",
month = "5",
doi = "10.1007/BF00177053",
language = "English",
volume = "19",
pages = "322--329",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "5",

}

TY - JOUR

T1 - Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin

AU - Paganelli, Giovanni

AU - Belloni, Carlo

AU - Magnani, Patrizia

AU - Zito, Felicia

AU - Pasini, Andrea

AU - Sassi, Isabella

AU - Meroni, Mario

AU - Mariani, Massimo

AU - Vignali, Mario

AU - Siccardi, Antonio G.

AU - Fazio, Ferruccio

PY - 1992/5

Y1 - 1992/5

N2 - A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 μg of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14% i.d. (range 8-18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56-70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.

AB - A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3-5 days later by 100-150 μg of indium-111 streptavidin, at the specific activity of 280-370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1-8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1-30:1) and 45:1 (range 12:1-120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1-30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01-0.3) for recurrences and 0.05 for primary tumour (range 0.005-0.2). Over 24-48 h 14% i.d. (range 8-18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56-70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.

KW - Intraperitoneal injection

KW - Monoclonal antibody

KW - Radioactive streptavidin

KW - Tumour pretargetting

KW - Two-step

UR - http://www.scopus.com/inward/record.url?scp=0026581622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026581622&partnerID=8YFLogxK

U2 - 10.1007/BF00177053

DO - 10.1007/BF00177053

M3 - Article

C2 - 1612093

AN - SCOPUS:0026581622

VL - 19

SP - 322

EP - 329

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 5

ER -